Background and Aims: When investigating and treating asthma in children, diag-
| INTRODUCTION
Asthma is a frequent disorder in children, with a reported prevalence varying from 4% to 22%. [1] [2] [3] [4] [5] In screening studies, approximately onethird of children with asthma have not been previously diagnosed with asthma. 3 Asthma medication prescription data have been used as a surrogate marker of asthma in attempts to estimate the prevalence of asthma in children. However, a recent study including 1744 children referred from general practitioners (GPs) to hospital specialist care for suspected asthma showed that approximately 30% of children not having specialist-confirmed asthma were treated with inhaled corticosteroids (ICS) by their GP, and conversely, 33% of the children having specialist-confirmed asthma were not treated with any asthma medication by the GP. 3 Thus, use of asthma medications may be nonspecific and non-complete for the presence of true asthma in any population, but the exact validity in population-based settings is unknown.
Several industrialized countries, including Denmark, have comprehensive administrative databases on medication prescriptions, which may be a strong resource in identifying children with asthma. 4, 6 In the present validation study, we aimed to utilize such data to identify all anti-asthmatic drug users among children in a well-defined rural area. We then set out to identify children with true asthma, diagnosed and validated by GPs and hospital doctors in the same geographical area, using the asthma definition of British Thoracic Society (BTS) and Global Initiative for Asthma (GINA) and national Danish guidelines. [7] [8] [9] We examined the validity and completeness of using prescription data to identify true asthma. We further investigated the pattern of asthma medication usage among children with and without confirmed asthma. We hypothesized that use of multiple anti-asthmatic drug prescriptions and use of drugs such as ICS or
Leukotriene receptor antagonists would be rare in children without true asthma.
| MATERIAL AND METHODS

| Setting
This study was a registry-based cross-sectional study, conducted in the Central Denmark region, Viborg County (population, 96 000 inhabitants, 20 181 children/youth 0-14 years of age). Denmark is a welfare state, with tax-financed universal access to health services.
Except for emergencies, patients' initial contact with the health care system is through their GPs, who act as gatekeepers and provide referrals to hospitals and specialist physicians as necessary. 10 Patients are normally registered with a single GP, and records from each GP can be assumed complete for an individual patient.
| Data sources
Data in our study were collected from:
-The Aarhus University Prescription Database 
| Study population
The universal use of CPR numbers, assigned to all Danish citizens at birth or immigration, enabled exact linkage between these data sources.
We identified a baseline study population of children with potential asthma, as follows: December 2010. Asthma diagnosis codes, Table 1. 3) In all these children, confirmed asthma diagnosis was based on international guidelines, Table 2 . Thus, GPs fulfilled a case record form for all children in order to verify the asthma diagnosis. When still in doubt of presence or absence of asthma in any patient, the child was referred to the hospital specialist outpatient clinic at Viborg Hospital in order to verify the asthma diagnosis. The GPs were paid a fee of 2500 DKR (335 EUR) for their participation in the project. Children who had received their asthma diagnosis by specialists at Viborg Hospital were defined as having true asthma. 12 Thereby, all children followed by either hospital specialists or GPs had their asthma diagnosis verified and validated according to international guidelines.
| Statistical analysis
The positive predictive value (PPV) of use of different anti-asthmatic drug regimens for the presence of true asthma was calculated as a proportion (ie, the numerator containing the number of children with confirmed asthma based on hospital diagnoses or GP validation, and the denominator containing the total number of children with the drug regimen). Sensitivity was calculated as the proportion of all children with confirmed asthma that were captured by different anti-asthmatic drug regimens. Statistical analysis was processed using STATA version 12.
| Ethics
The study was approved by the Danish Data Protection Agency 
| RESULTS
In total, 2053 children were included in the study from hospital and did not have confirmed asthma even though they had redeemed any type of inhaled anti-asthmatic drug at least once. Age and sex of children with and without confirmed asthma are shown in Table 3, showing that the proportion of young children (0-5 years old) was higher in the unconfirmed versus confirmed asthma group. 
| Validity of asthma treatment for defining true asthma
In general, there was an increasing probability of having true asthma the more prescriptions redeemed, as expected (Table 5) . Thus, 79.3%
(794/1001) of children having redeemed at least one prescription for ICS had true asthma, increasing to 90.6% (348/384) of those who 
| DISCUSSION
Our study has characterized the pattern of asthma medication usage among children with true asthma, ie, verified doctor diagnosed asthma, in a Danish rural area. Our research hypothesis was that physicians, in general, followed guidelines for anti-asthmatic treatment.
For example, children with confirmed asthma who had at least two prescriptions for inhaled Beta2-agonists should also be treated with Our study estimated the predictive value of different asthma medications for true asthma in the age group 0 to 14 years by using register-based prescription data as a proxy for asthma. We found that some asthma medication can be used as a reasonable proxy for true asthma diagnoses. This may be specific to Danish databases or prove itself as a general improvement of validity of data from registers when comparing to previous studies in Germany and The Netherlands. [16] [17] [18] When choosing the "cut-off" of at least two prescriptions redeemed, not for the same drug but for two different R03 drugs, the PPV was 80%, with a moderate sensitivity of close to 60%. Similar accuracy was found with just one prescription for ICS.
| Strengths and limitations
Asthma is a clinical diagnosis made by physicians on the basis of a patient's symptoms and medical history, a clinical examination, and exclusion of differential diagnosis. A strength of the study was that asthma diagnoses were individually validated in all children by doctors specifically trained and educated in asthma diagnosing guidelines.
Our use of complete prescription registries and the validation process afterwards regarding asthma diagnosis reduced any selection and recall bias. We believe that our validation data may be generalized to national populations of individuals with childhood asthma due to the fact that Viborg rural area is a larger commune of Jutland and is inhabited by 2% of the Danish population, and also by the fact that almost all GPs, 91% (81/89) within the rural area of Viborg, were included. However, we did not include all children in Viborg County to be screened/examined for asthma, and completeness for true asthma may, thus, be underestimated due to undetected children.
| CONCLUSION
Anti-asthmatic drug prescription data in Viborg County could be used to identify children with confirmed asthma with reasonable accuracy.
The observed pattern of anti-asthmatic medication usage among children with and without true asthma suggests that there is still room for therapeutic improvement. The outcome showing a PPV of 80.2% and a sensitivity of 59% of the cohort of children with confirmed asthma established in our validation study may be used for future longitudinal population-based surveillance and research. This study yields results that show how future studies researching asthma in children can benefit from using registry-based epidemiological data.
